MedPath

Safety and efficacy of cord blood transplantation for hematologic malignancies (OCU 9-2)

Phase 2
Conditions
Acute myeloid leukemia AML with multilineage dysplasia Myelodysplastic syndrome Acute lymphoblastic leukemia Chronic myeloid leukemia Adult T cell leukemia/lymphoma Malignant lymphoma
Registration Number
JPRN-UMIN000002214
Lead Sponsor
Hematology, Osaka City University, Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1. Dysfunction of major organ which meets any of the following criteria. a. T-Bil > 2.0mg/dl b. Cre > 2.0mg/dl c. EF >30% d. %VC <30%, FEV1.0% <40% or SaO2 < 50mmHg on room air (SpO2 <90%) e. AST: beyond 3 times of UNL 2. Active infection 3. Poorly controlled diabetes mellitus despite the use of insulin 4. Poorly controlled hypertention 5. Severe complications including heart failure, coronary failure, myocardial infarction within the last 3 months, liver cirrhosis and interstitial pneumonia 6. Pregnant, nursing of possible fertile woman 7. Severe mental disorder who is unlikely to be able to participate in the study 8. A history of hypersensitivity or allergy to any drugs in conditioning regimen of this transplantation 9. HIV antibody positivity 10. No indication for this study judged by physician in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath